Ponatinib coronary microangiopathy: novel bedside diagnostic approach and management with N-acetylcysteine

Blood Adv. 2020 Sep 8;4(17):4083-4085. doi: 10.1182/bloodadvances.2020002644.

Abstract

  1. Ponatinib produces a coronary microangiopathy that mimics myocardial infarction and can be detected rapidly by contrast echocardiography.

  2. N-acetylcysteine therapy can potentially resolve ischemic complications caused by ponatinib-related microangiopathy.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Acetylcysteine / therapeutic use
  • Humans
  • Imidazoles / therapeutic use
  • Pyridazines*
  • Vascular Diseases*

Substances

  • Imidazoles
  • Pyridazines
  • ponatinib
  • Acetylcysteine